A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
Public ClinicalTrials.gov record NCT05551117. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study CP-MGC018-03 is an open-label, two-part, Phase 2 study. Part 1 of the study will enroll participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with one prior androgen receptor axis-targeted therapy (ARAT). ARAT includes abiraterone, enzalutamide, or apalutamide. Participants may have received up to 1 prior docetaxel-containing regimen, but no other chemotherapy agents. This part of the study will assess the efficacy and tolerability of vobramitamab duocarmazine (MGC018) in two experimental arms (2.0 mg/kg every 4 weeks \[Q4W\] and 2.7 mg/kg Q4W) . Approximately 100 participants will be randomized 1:1. Part 2 of the study will enroll participants with locally advanced or metastatic solid tumors. Participants must have progressive following at least 1 prior line of standard chemotherapy for advanced or metastatic disease. Participants will receive vobramitamab duocarmazine at a dose of 2.7 mg/kg every 4 weeks. Up to 200 participants may be enrolled in Part 2. In both parts, vobramitamab duocarmazine will be administered intravenously (IV) in clinic on Day 1 of each 4-week cycle. Vobramitamab duocarmazine will be administered until criteria for treatment discontinuation are met. Participants will undergo regular testing for signs of disease progression using computed tomography (CT) scans, magnetic resonance imaging (MRI), bone scans, and prostate-specific antigen (PSA) blood tests. Routine examinations and blood tests will be performed and evaluated by the study doctor.
Study identification
- NCT ID
- NCT05551117
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 192 participants
Conditions and interventions
Conditions
- Castration-Resistant Prostatic Cancer
- Androgen-Independent Prostatic Cancer
- Androgen-Insensitive Prostatic Cancer
- Androgen-Resistant Prostatic Cancer
- Hormone Refractory Prostatic Cancer
- Anal Cancer
- Anal Neoplasm
- Carcinoma, Squamous Cell of Head and Neck
- Head and Neck Squamous Cell Carcinoma
- Laryngeal Squamous Cell Carcinoma
- Oral Squamous Cell Carcinoma
- Malignant Melanoma
- Melanoma
- Non-small Cell Lung Cancer
- Non-small Cell Carcinoma
- Small-cell Lung Cancer
- Small Cell Carcinoma
Interventions
- vobramitamab duocarmazine 2.0 mg (Arm A) Biological
- vobramitamab duocarmazine 2.7 mg (Arm B) Biological
- vobramitamab duocarmazine Biological
- Abiraterone Drug
- Enzalutamide Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 12, 2023
- Primary completion
- Jul 3, 2024
- Completion
- Jan 22, 2025
- Last update posted
- Feb 8, 2026
2023 – 2025
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Compassionate Cancer Care Medical Group | Fountain Valley | California | 92708 | — |
| University of California Los Angeles (UCLA) Community Cancer Care | Los Angeles | California | 90095 | — |
| The University of Florida Health System - UF Health Urology - Jacksonville | Jacksonville | Florida | 32209 | — |
| Mid Florida Hematology and Oncology Center | Orange City | Florida | 32763 | — |
| Pontchartrain Cancer Center | Covington | Louisiana | 70433 | — |
| The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland | 21231 | — |
| Barbara Ann Karmanos Cancer Institute - Hudson-Webber Cancer Research Center | Detroit | Michigan | 48201 | — |
| Masonic Cancer Center, University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| VA Portland Health Care Services | Portland | Oregon | 97239 | — |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | 29572 | — |
| University of Virginia Comprehensive Cancer Center | Charlottesville | Virginia | 22908 | — |
| Virginia Cancer Specalists | Fairfax | Virginia | 22031 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05551117, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 8, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05551117 live on ClinicalTrials.gov.